NCT00258687View on ClinicalTrials.gov

Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

December 31, 2020

Conditions
Sarcoma, Clear CellSarcoma, Alveolar Soft PartRenal Cell CarcinomaMelanoma
Interventions
BIOLOGICAL

GVAX

4 vaccines every two weeks

Trial Locations (2)

02115

Children's Hospital Boston, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Boston Children's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00258687 - Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | Biotech Hunter | Biotech Hunter